Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB08892_nanopub.RAuVwe61zWeEO95evdepz9R916tHCkghRAIIChJt6RwCg#assertion>. }
Showing items 1 to 13 of
13
with 100 items per page.
- drugbank:DB08892 type drugbank_vocabulary:Drug assertion.
- drugbank:DB08892 label "Arbaclofen Placarbil [drugbank:DB08892]" assertion.
- drugbank:DB08892 seeAlso DB08892 assertion.
- drugbank:DB08892 description "Arbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned by XenoPort in 2011 for the treatment of GERD. On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis." assertion.
- drugbank:DB08892 identifier "drugbank:DB08892" assertion.
- drugbank:DB08892 title "Arbaclofen Placarbil" assertion.
- drugbank:DB08892 drugbank_vocabulary:x-cas cas:847353-30-4 assertion.
- drugbank:DB08892 drugbank_vocabulary:drugbank-id "DB08892" assertion.
- drugbank:DB08892 bio2rdf_vocabulary:x-identifiers.org DB08892 assertion.
- drugbank:DB08892 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB08892" assertion.
- drugbank:DB08892 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB08892 bio2rdf_vocabulary:identifier "DB08892" assertion.
- drugbank:DB08892 drugbank_vocabulary:x-kegg kegg:D08861 assertion.